Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;11(8):2636-2646.
doi: 10.21037/tcr-22-529.

Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer

Xiao-Xiang Jie #  1 , Meng Zhang #  1 , Ming Du #  1 , Qing-Qing Cai  1   2 , Qing Cong  1 , Cong-Jian Xu  1   2 , Xiao-Yan Zhang  1   2
Affiliations

Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer

Xiao-Xiang Jie et al. Transl Cancer Res. 2022 Aug.

Abstract

Background: Circulating tumor cells (CTCs) have considered to be promising liquid biopsy in cancer due to the intact information of whole cells and the potential to reflect micrometastasis. However, CTCs research are extremely limited in ovarian cancer, probably due to their rarity. The predictive value of CTCs and circulating tumor microemboli (CTM) in metastasis remains to be elucidated in ovarian cancer. This study tried to identify CTCs/CTM in ovarian cancer with considerably positive rate. To preliminarily identify the invasive capacity of CTCs/CTM, the epithelial-mesenchymal transition (EMT) patterns of CTCs/CTM was evaluated. Moreover, for comprehensive understanding of invasiveness of disseminated cells in ovarian cancer, EMT pattern of exfoliated tumor cells in ascites were also confirmed in this study.

Methods: Peripheral blood samples and ascites samples were collected from 22 ovarian cancer patients. The Microfiltration combined with morphological analysis was used to detect CTC single cells or cell clusters. Microfiltration combined with morphological analysis was applied in the CTC isolation and identification. EMT was evaluated by immunofluorescence via markers including vimentin and cytokeratin.

Results: Microfiltration combined with morphological analysis was introduced to detect CTCs/CTM with a positivity rate of 40.9% in ovarian cancer patients. The number of CTC varied from 1 to 8, with CTM number from 4 to 30. CTCs/CTM of all samples have experienced EMT process. Vimentin was expressed in all CTC samples and all tumor cells in ascites, while cytokeratin was expressed in 44.4% (4/9) of CTC samples. There were no significant differences of the clinical parameters between the CTC-positive and CTC-negative patients.

Conclusions: This study showed that both CTCs/CTM and detached tumor cells in ascites might have undergone complete or partial EMT in ovarian cancer. Moreover, microfiltration combined with cytomorphological analysis showed a considerable CTC detection rate.

Keywords: Ovarian neoplasms; circulating tumor cells (CTCs); epithelial-mesenchymal transition; metastasis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-529/coif). CJX reports funding made to the Obstetrics and Gynecology Hospital of Fudan University from the Shanghai Medical Center of Key Programs for Female Reproductive Diseases (grant No. 2017ZZ01016). XYZ reports funding made to the Obstetrics and Gynecology Hospital of Fudan University from the National Natural Science Foundation of China (grant No. 82172747). The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flow chart of CTCs/CTM enrichment and detection. CTCs, circulating tumor cells; CTM, circulating tumor microemboli; RBC, red blood cells; WBC, white blood cells.
Figure 2
Figure 2
HE staining and immunofluorescent staining of CTCs/CTM. (A) H&E staining of isolated CTCs and CTM. (B) Immunofluorescent staining for vimentin and cytokeratin in CTCs. (C) Immunofluorescent staining for vimentin and cytokeratin in CTM. (Scale bar: 50 µm for HE staining; 50 µm for immunofluorescent staining). DAPI, 4',6-diamidino-2-phenylindole; CTCs, circulating tumor cells; CTM, circulating tumor microemboli; HE, hematoxylin and eosin.
Figure 3
Figure 3
HE staining and immunofluorescent staining of detached tumor cells in ascites. (A) HE staining of isolated tumor cells and cell clusters in ascites. (B) Immunofluorescent staining for vimentin and cytokeratin in disseminated tumor cells in ascites. (C) Immunofluorescent staining for vimentin and cytokeratin in disseminated tumor cell clusters in ascites. (Scale bar: 50 µm for HE staining; 50 µm for immunofluorescent staining). DAPI, 4',6-diamidino-2-phenylindole; HE, hematoxylin and eosin.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin 2021;71:7-33. 10.3322/caac.21654 - DOI - PubMed
    1. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 2019;69:280-304. 10.3322/caac.21559 - DOI - PubMed
    1. Corrado G, Salutari V, Palluzzi E, et al. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther 2017;17:1147-58. 10.1080/14737140.2017.1398088 - DOI - PubMed
    1. Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet 2019;393:1240-53. 10.1016/S0140-6736(18)32552-2 - DOI - PubMed
    1. Asante DB, Calapre L, Ziman M, et al. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? Cancer Lett 2020;468:59-71. 10.1016/j.canlet.2019.10.014 - DOI - PubMed